J Natl Compr Canc Netw 2022 Sep
FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma.
Related Questions
How did the SWOG 1505 clinical trial influence your clinical practice?
New answer by Medical Oncologist at Mayo Clinic (September 10, 2023)
We typically use FOLFIRINOX as well and monitor with FDG PET, MRI, and CT. Metabolic response is associated with path response (not surprising) and also OS. The results from o...